SciELO - Scientific Electronic Library Online

1. Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J Am Coll Cardiol 2004; 43: 1137–44. [ Links ]

2. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998; 98: 2334–51. [ Links ]

3. Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation. 2000; 102: 649–54. [ Links ]

4. Puranik R, Chow CK, Duflou JA, Kilborn MJ, McGuire MA. Sudden death in the young. Heart Rhythm. 2005; 2: 1277–82. [ Links ]

5. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005; 85: 1205–53. [ Links ]

6. Herrlin KMMT. A case of cardiac syncope. Acta Paediatriva 1953; 391. [ Links ]

7. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995; 80: 795–803. [ Links ]

8. Wang Q, Shen J, Li Z, et al. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 1995; 4: 1603–7. [ Links ]

9. Beccaria E, Brim S, Gaita F, Giustetto C, Conti M. Torsade de pointes during an atropine sulfate test in a patient with congenital long QT syndrome. Cardiología 1989; 34: 1039–43. [ Links ]

10. Jervell A, Lange–Nielsen F. Congenital deaf–mutism, functional heart disease with prolongation of the Q–T interval and sudden death. Am Heart J 1957; 54: 59–68. [ Links ]

11. Romano C, Gemme G, Pongiglione R. Rare cardiac arrhythmias of the pediatric age. I. Repetitive Paroxysmal Tachycardia. Minerva Pediatr 1963; 15: 1155–64. [ Links ]

12. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805–11. [ Links ]

13. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005; 294: 2975–80. [ Links ]

14. Nerbonne JM. Molecular basis of functional voltage–gated K+ channel diversity in the mammalian myocardium. J Physiol 2000; 525 Pt 2: 285–98. [ Links ]

15. Crozier IG, Loughnan A, Dow LJ, Low CJ, Ikram H. Congenital long QT syndrome in adults. N Z Med J 1989; 102: 340–1. [ Links ]

16. McCrossan ZA, Abbott GW. The MinK–related peptides. Neuropharmacology 2004; 47: 787–821. [ Links ]

17. Abbott GW, Goldstein SA. Potassium channel subunits encoded by the KCNE gene family: physiology and pathophysiology of the MinK–related peptides (MiRPs). Mol Interv 2001; 1: 95–107. [ Links ]

18. Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1–KCNE1 potassium channel. Science 2002; 295: 496–9. [ Links ]

19. Schwartz PJ. Another role for the sympathetic nervous system in the long QT syndrome? J Cardiovasc Electrophysiol 2001; 12: 500–2. [ Links ]

20. Goldin AL, Barchi RL, Caldwell JH, et al. Nomenclature of voltage–gated sodium channels. Neuron 2000; 28: 365–8. [ Links ]

21. Gellens ME, George AL, Jr., Chen LQ, et al. Primary structure and functional expression of the human cardiac tetrodotoxin–insensitive voltage–dependent sodium channel. Proc Nati Acad Sci USA 1992; 89: 554–8. [ Links ]

22. Ko SH, Lenkowski PW, Lee HC, Mounsey JP, Patel MK. Modulation of Na(v)1.5 by betal— and beta3–subunit co–expression in mammalian cells. Pflugers Arch 2005; 449: 403–12. [ Links ]

23. Maier SK, Westenbroek RE, McCormick KA, Curtis R, Scheuer T, Catterall WA. Distinct subcellular localization of different sodium channel alpha and beta subunits in single ventricular myocytes from mouse heart. Circulation 2004; 109: 1421–7. [ Links ]

24. Wollner DA, Messner DJ, Catterall WA. Beta 2 subunits of sodium channels from vertebrate brain. Studies with subunit–specific antibodies. J Biol Chem 1987; 262: 14709–15. [ Links ]

25. Isom LL, Ragsdale DS, De Jongh KS, et al. Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell 1995; 83: 433–42. [ Links ]

26. Morgan K, Stevens EB, Shah B, et al. Beta 3: an additional auxiliary subunit of the voltage–sensitive sodium channel that modulates channel gating with distinct kinetics. Proc Nati Acad Sci USA 2000; 97: 2308–13. [ Links ]

27. Yu FH, Westenbroek RE, Silos–Santiago I, et al. Sodium channel beta4, a new disulfide–linked auxiliary subunit with similarity to beta2. J Neuro sci 2003; 23: 7577–85. [ Links ]

28. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype–phenotype correlation in the long–QT syndrome: gene–specific triggers for life–threatening arrhythmias. Circulation 2001; 103: 89–95. [ Links ]

29. Beaufort–Krol GC, van den Berg MP, Wilde AA, et al. Developmental aspects of long QT syndrome type 3 and Brugada syndrome on the basis of a single SCN5A mutation in childhood. J Am Coll Cardiol 2005; 46: 331–7. [ Links ]

30. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin–B mutation causes type 4 long–QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634–9. [ Links ]

31. Mohler PJ, Bennett V. Ankyrin–based cardiac arrhythmias: a new class of channelopathies due to loss of cellular targeting. Curr Opin Cardiol 2005; 20: 189–93. [ Links ]

32. Mohler PJ, Splawski I, Napolitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin–B function. Proc Nati Acad Sci USA 2004; 101: 9137–42. [ Links ]

33. Splawski I, Tristani–Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997; 17: 338–40. [ Links ]

34. Abbott GW, Sesti F, Splawski I, et al. MiRPl forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175–87. [ Links ]

35. Plaster NM, Tawil R, Tristani–Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105: 511–19. [ Links ]

36. Yoon G, Oberoi S, Tristani–Firouzi M, et al. Andersen–Tawil syndrome: Prospective cohort analysis and expansion of the phenotype. Am J Med Genet A 2006; 140: 312–21. [ Links ]

37. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119: 19–31. [ Links ]

38. Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L–type calcium channel mutations. Proc Nati Acad Sci USA 2005; 102: 8089–96; discussion 8086–8. [ Links ]

39. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: a common cause of severe long–QT syndrome. Circulation 2004; 109: 1834–41. [ Links ]

40. Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange–Nielsen Syndrome. Natural History, Molecular Basis, and Clinical Outcome. Circulation 2006. [ Links ]

41. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993; 88: 782–4. [ Links ]

42. Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005; 2: 569–74. [ Links ]

43. Cowan JC, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61: 83–7. [ Links ]

44. Brugada RHK, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, et al. Sudden death associated with short–QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30–35. [ Links ]

45. Antzelevitch C, Belardinelli L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol 2006; 17 (Suppl. 1): S79–S85. [ Links ]

46. Yamaguchi M, Shimizu M, Ino H, et al. T wave peak–to–end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003; 105: 671–6. [ Links ]

47. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994; 89: 1681–9. [ Links ]

48. Napolitano C, Priori SG, Schwartz PJ. Significance of QT dispersion in the long QT syndrome. Prog Cardiovasc Dis 2000; 42: 345–50. [ Links ]

49. Perkiomaki JS, Zareba W, Nomura A, Andrews M, Kaufman ES, Moss AJ. Repolarization dynamics in patients with long QT syndrome. J Cardiovasc Electrophysiol 2002; 13: 651–6. [ Links ]

50. Zareba W, Moss AJ, le Cessie S, Hall WJ. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol 1994; 23: 1541–6. [ Links ]

51. Narayan SM. T–wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 2006; 47: 269–81. [ Links ]

52. Beinder E, Grancay T, Menendez T, Singer H, Hofbeck M. Fetal sinus bradycardia and the long QT syndrome. Am J Obstet Gynecol 2001; 185: 743–7. [ Links ]

53. Lupoglazoff JM, Denjoy I, Villain E, et al. Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. J Am Coll Cardiol 2004; 43: 826–30. [ Links ]

54. Scott WA, Dick M, 2nd. Two:one atrioventricular block in infants with congenital long QT syndrome. Am J Cardiol 1987; 60: 1409–10. [ Links ]

55.  Garson A Jr., Dick M, 2nd, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993; 87: 1866–72. [ Links ]

56. Trippel DL, Parsons MK, Gillette PC. Infants with long–QT syndrome and 2:1 atrioventricular block. Am Heart J 1995; 130: 1130–4. [ Links ]

57. Gorgels AP, Al Fadley F, Zaman L, Kantoch MJ, Al Halees Z. The long QT syndrome with impaired atrioventricular conduction: a malignant variant in infants. J Cardiovasc Electrophysiol 1998; 9: 1225–32. [ Links ]

58. van Hare GF, Franz MR, Rogé C, Scheinman MM. Persistent functional atrioventricular block in two patients with prolonged QT intervals: elucidation of the mechanism of block. Pacing Clin Electrophysiol 1990; 13: 608–18. [ Links ]

59. Hoorntje T, Alders M, van Tintelen P, et al. Homozygous premature truncation of the HERG protein: the human HERG knockout. Circulation 1999; 100: 1264–7. [ Links ]

60. Pilippo K, Laitinen P, Swan H, et al. Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns. J Am Coll Cardiol 2000; 35: 1919–25. [ Links ]

61. Lupoglazoff JM, Cheav T, Baroudi G, et al. Homozygous SCN5A mutation in long–QT syndrome with functional two–to–one atrioventricular block. Circ Res 2001; 89: E16–E21. [ Links ]

62. Noda T, Shimizu W, Satomi K, et al. Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. Eur Heart J 2004; 25: 2149–54. [ Links ]

63. Liu J, Laurita KR. The mechanism of pause–induced torsade de pointes in long QT syndrome. J Cardiovasc Electrophysiol 2005; 16: 981–7. [ Links ]

64. Viskin S, Fish R, Zeltser D, et al. Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent? Heart 2000; 83: 661–6. [ Links ]

65. el–Sherif N, Turitto G. The long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol 1999; 22: 91–110. [ Links ]

66. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST–T–wave patterns and repolarization parameters in congenital long–QT syndrome: ECG findings identify genotypes. Circulation 2000; 102: 2849–55. [ Links ]

67. Chang IK, Shyu MK, Lee CN, et al. Prenatal diagnosis and treatment of fetal long QT syndrome: a case report. Prenat Diagn 2002; 22: 1209–12. [ Links ]

68. Miller TE, Estrella E, Myerburg RJ, et al. Recurrent third–trimester fetal loss and maternal mosaicism for long–QT syndrome. Circulation 2004; 109: 3029–34. [ Links ]

69. Tester DJ, McCormack J, Ackerman MJ. Prenatal molecular genetic diagnosis of congenital long QT syndrome by strategic genotyping. Am J Cardiol 2004; 93: 788–91. [ Links ]

70. Fitzgerald PT, Ackerman MJ. Drug–induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2005; 2: S30–7. [ Links ]

71. Roden DM. Drug–induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013–22. [ Links ]

72. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45:415–27. [ Links ]

73. Abriel H, Schlapfer J, Keller DI, et al. Molecular and clinical determinants of drug–induced long QT syndrome: an iatrogenic channelopathy. Swiss Med Wkly 2004; 134: 685–94. [ Links ]

74. Sun Z, Milos PM, Thompson JF, et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide–induced Torsades de Pointes. J Mol Cell Cardiol 2004; 37: 1031–9. [ Links ]

75. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003; 78: 1479–87. [ Links ]

76. Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenie susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm. 2004; 1: 600–7. [ Links ]

77. Ye B, Valdivia CR, Ackerman MJ, Makielski JC. A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. Physiol Genomics 2003; 12: 187–93. [ Links ]

78. Makielski JC, Ye B, Valdivia CR, et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res 2003; 93: 821–8. [ Links ]

79. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 2006; 259: 59–69. [ Links ]

80. Plant LD, Bowers PN, Liu Q, et al. A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest 2006; 116: 430–5. [ Links ]

81. Walker BD, Krahn AD, Klein GJ, Skanes AC, Yee R. Burst bicycle exercise facilitates diagnosis of latent long QT syndrome. Am Heart J 2005; 150: 1059–63. [ Links ]

82. Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano–Ward inherited long QT syndrome. Am J Cardiol 1991; 68: 498–503. [ Links ]

83. Takenaka K, Ai T, Shimizu W, et al. Exercise stress test amplifies genotype–phenotype correlation in the LQT1 and LQT2 forms of the long–QT syndrome. Circulation 2003; 107: 838–44. [ Links ]

84. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol 1999; 34: 823–9. [ Links ]

85. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene–specific therapy. Circulation 1995; 92: 3381–6. [ Links ]

86. Schwartz PJ. Management of long QT syndrome. Nat Clin Pract Cardiovasc Med 2005; 2: 346–51. [ Links ]

87. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005; 2: 507–17. [ Links ]

88. Zhang L, Vincent GM, Baralle M, et al. An intronic mutation causes long QT syndrome. J Am Coll Cardiol 2004; 44: 1283–91. [ Links ]

89. Priori SG. Inherited arrhythmogenic diseases: the complexity beyond monogenic disorders. Circ Res 2004; 94: 140–5. [ Links ]

90. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long–QT syndrome: clinical impact. Circulation 1999; 99: 529–33. [ Links ]

91. Schwartz PJ. Clinical applicability of molecular biology: the case of the long QT syndrome. Curr Control Trials Cardiovasc Med 2000; 1: 88–91. [ Links ]

92. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long–QT syndrome with mutations in the pore region of the human ether–a–go–go–related gene potassium channel. Circulation 2002; 105: 794–9. [ Links ]

93. Yao CT, Wang JN, Tsai YC, Lin CS, Wu JM. Congenital long QT syndrome with functionally impaired atrioventricular conduction: successful treatment by mexiletine and propranolol. J Formos Med Assoc 2002; 101: 291–3. [ Links ]

94. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine–induced QT interval prolongation: a gene–specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002; 77: 413–21. [ Links ]

95. Khositseth A, Hejlik J, Shen WK, Ackerman MJ. Epinephrine–induced T–wave notching in congenital long QT syndrome. Heart Rhythm 2005; 2: 141–6. [ Links ]

96. Shimizu W, Noda T, Takaki H, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm 2004; 1: 276–83 [ Links ]

97. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long–QT syndrome. N Engl J Med 2003; 348: 1866–74. [ Links ]

98. Locati EH, Zareba W, Moss AJ, et al. Age–and sex–related differences in clinical manifestations in patients with congenital long–QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97: 2237–44. [ Links ]

99. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long–QT syndrome. International Long–QT Syndrome Registry Research Group. N Engl J Med 1998; 339: 960–5. [ Links ]

100. Khositseth A, Tester DJ, Will ML, Bell CM, Ackerman MJ. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004; 1: 60–4. [ Links ]

101. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998; 97: 451–6. [ Links ]

102. Itoh T, Kikuchi K, Odagawa Y, et al. Correlation of genetic etiology with response to beta–adrenergic blockade among symptomatic patients with familial long–QT syndrome. J Hum Genet 2001; 46: 38–40. [ Links ]

103. Chatrath R, Bell CM, Ackerman MJ. Beta–blocker therapy failures in symptomatic probands with genotyped long–QT syndrome. Pediatr Cardiol 2004; 25: 459–65. [ Links ]

104. Dorostkar PC, Eldar M, Belhassen B, Scheinman MM. Long–term follow–up of patients with long–QT syndrome treated with beta–blockers and continuous pacing. Circulation 1999; 100: 2431–6. [ Links ]

105. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta–blockers. JAMA 2004; 292: 1341–4. [ Links ]

106. Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with new SCN5A mutation: mutation–specific therapy for long–QT syndrome? Circulation 2000; 101: 1698–706. [ Links ]

107. Schulze–Bahr E, Fenge H, Etzrodt D, et al. Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart 2004; 90: 13–6. [ Links ]

108. Kehl HG, Haverkamp W, Rellensmann G, et al. Images in cardiovascular medicine. Life–threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT–syndrome–3. Circulation 2004; 109: e205–e206. [ Links ]

109. Shimizu W, Kurita T, Matsuo K, et al. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long–QT syndrome. Circulation 1998; 97: 1581–8. [ Links ]

110. Etheridge SP, Compton SJ, Tristani–Firouzi M, Mason JW. A new oral therapy for long QT syndrome: long–term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003; 42: 1777–82. [ Links ]

111. Khan IA, Gowda RM. Novel therapeutics for treatment of long–QT syndrome and torsade de pointes. Int J Cardiol 2004; 95: 1–6. [ Links ]

112. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 2000; 11: 593–600. [ Links ]

113. Moss AJ, Liu JE, Gottlieb S, Locati EH, Schwartz PJ, Robinson JL. Efficacy of permanent pacing in the management of high–risk patients with long QT syndrome. Circulation 1991; 84: 1524–9. [ Links ]

114. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter–defibrillator therapy in patients with congenital long–QT syndrome: a long–term follow–up. Heart Rhythm 2005; 2: 497–504. [ Links ]

115. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high–risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003; 14: 337–41. [ Links ]

116. Kaufman ES. Saving lives in congenital long QT syndrome: who benefits from implantable cardioverter defibrillator therapy? J Cardiovasc Electrophysiol 2003; 14: 342–3. [ Links ]

117. Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med 1971; 285: 903–4. [ Links ]

118. Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation 1991; 84: 503–11. [ Links ]

119. Wang LX. Role of left cardiac sympathetic denervation in the management of congenital long QT syndrome. J Postgrad Med 2003; 49: 179–81. [ Links ]

120. Wang L, Feng G. Left cardiac sympathetic denervation as the first–line therapy for congenital long QT syndrome. Med Hypotheses 2004; 63: 438–41. [ Links ]

121. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high–risk patients affected by the long–QT syndrome. Circulation 2004; 109: 1826–33. [ Links ]

122. Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long–QT and Brugada syndromes. Circulation 2003; 108: 925–8. [ Links ]

123. Di Paolo M, Luchini D, Bloise R, Priori SG. Postmortem molecular analysis in victims of sudden unexplained death. Am J Forensic Med Pathol 2004; 25: 182–4. [ Links ]

124. Ackerman MJ, Tester DJ, Porter CJ, Edwards WD. Molecular diagnosis of the inherited long–QT syndrome in a woman who died after near–drowning. N Engl J Med 1999; 341: 1121–5. [ Links ]

125. Chugh SS, Senashova O, Watts A, et al. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol 2004; 43: 1625–9. [ Links ]

126. Tester DJ, Ackerman MJ. Sudden infant death syndrome: how significant are the cardiac channelopathies? Cardiovasc Res 2005; 67: 388–96. [ Links ]